Synthorx Inc. ,a biotechnology company using synthetic biology to discover and develop novel protein therapeutics, has named Dr. Laura Shawver president, director and CEO. Prior to joining Syntho
For the past four years, Takeda's plans for a full-scale entry into India have remained just that – plans on paper. But will it be a laggard for much longer in this fast-changing key emerging market?
Boehringer Ingelheim initiated a Phase I clinical trial for the beta-secretase (BACE) inhibitor developed under a 2009 collaboration agreement with Vitae Pharmaceuticals, triggering a $14m milestone p
Merck & Co's MK-8931 has successfully cleared an early hurdle in the race to find a product that might treat Alzheimer's disease through beta secretase enzyme (BACE) inhibition. The firm reported posi